Skip to main content

Advertisement

SpringerLink
Log in

Troponin in Cardiovascular Disease Prevention: Updates and Future Direction

  • Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Cardiac troponin has been well described as the preferred biomarker for diagnosis of myocardial infarction due to the high sensitivity and specificity for myocardial injury. Numerous other conditions apart from acute coronary syndrome can also lead to small elevations in troponin levels. However, the use of cTn as prognostic biomarker for the primary assessment of cardiovascular risk in asymptomatic patient has only recently been described. And with the development of newer generations of high-sensitivity cardiac troponin assays that can detect 10-fold lower concentrations of troponin, the potential value cTn in the prevention and management of asymptomatic cardiovascular disease has come to the fore. This review provides an overview of the transition of cardiac troponin as a marker of acute myocardial injury to one that detects sub-clinical injury. Evidence continues to show that high-sensitivity troponin is emerging as one of the most powerful prognostic biomarkers for the assessment of cardiovascular risk in the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–53.

    Article  CAS  PubMed  Google Scholar 

  2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.

    Article  PubMed  Google Scholar 

  4. Wang T, Gona P, Larson M, Tofler G, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–9.

    Article  CAS  PubMed  Google Scholar 

  5. Vasan R. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335–62.

    Article  PubMed  Google Scholar 

  6. Singh V, Martinezclark P, Pascual M, Shaw E, OʼNeill W. Cardiac biomarkers—the old and the new: a review. Coron Artery Dis. 2010;21(4):244–56.

    Article  PubMed  Google Scholar 

  7. Henry J, McPherson R, Pincus M, Abraham N. Henry’s clinical diagnosis and management by laboratory methods.

  8. Harrison T, Longo D, Kasper D, Jameson J, Fauci A, Hauser S, et al. Harrison’s principles of internal medicine. New York: McGraw-Hill; 2012.

    Google Scholar 

  9. Antman EM, Grudzien C, Mitchell RN, et al. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. 1997;133:596–8.

    Article  CAS  PubMed  Google Scholar 

  10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7):e1–e157.

    Article  PubMed  Google Scholar 

  11. Lindahl B, Venge P, Wallentin L, for the FRISC Study Group. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation. 1996;93:1651–7.

    Article  CAS  PubMed  Google Scholar 

  12. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142(9):786–91.

    Article  PubMed  Google Scholar 

  13. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J. 1999;138:95–9.

    Article  CAS  PubMed  Google Scholar 

  14. Khan N. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112(20):3088–96.

    Article  CAS  PubMed  Google Scholar 

  15. Bessière F, Khenifer S, Dubourg J, Durieu I, Lega J. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med. 2013;39(7):1181–9.

    Article  PubMed  Google Scholar 

  16. Becattini C, Vedovati M, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–33.

    Article  CAS  PubMed  Google Scholar 

  17. Faiz K, Thommessen B, Einvik G, Omland T, Rønning O. Prognostic value of high-sensitivity cardiac troponin T in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(2):241–8.

    Article  PubMed  Google Scholar 

  18. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–12. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the younger age group (age 30–65 years).

    Article  PubMed  Google Scholar 

  19. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–76. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the middle aged group (age 54–74).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494–502. One of the three large multi-center prospective observational studies to determine the prevalence/importance of detectable Hs-Tn in a general asymptomatic population without preexisting CHD or HF. This study included the older age group (age > 65).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958–65.

    Article  CAS  PubMed  Google Scholar 

  22. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol. 2008;52:450–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16.

    Article  CAS  PubMed  Google Scholar 

  24. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project. Circulation. 2010;121:2388–97.

    Article  PubMed  Google Scholar 

  25. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–68.

    Article  CAS  PubMed  Google Scholar 

  26. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. Prevention of events with angiotensin converting enzyme inhibition trial I. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.

    Article  CAS  PubMed  Google Scholar 

  28. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High‐sensitivity cardiac troponin I measurement for risk stratification in a stable high‐risk population. Clin Chem. 2011;57:1146–53.

    Article  CAS  PubMed  Google Scholar 

  29. Peacock IV WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26.

    Article  CAS  PubMed  Google Scholar 

  30. Jungbauer CG, Riedlinger J, Buchner S, Birner C, Resch M, Lubnow M, et al. High‐sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N‐terminal pro‐B‐type natriuretic peptide. Clin Chem Lab Med. 2011;49:1899–906.

    Article  CAS  PubMed  Google Scholar 

  31. Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, et al. Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13:726–33.

    Article  CAS  PubMed  Google Scholar 

  32. Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J. 2010;159:63–7.

    Article  CAS  PubMed  Google Scholar 

  33. Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125:280–8.

    Article  CAS  PubMed  Google Scholar 

  34. Nagarajan V, Hernandez AV, Tang WH. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012;98:1778–86.

    Article  PubMed  Google Scholar 

  35. Kawahara C, Tsutamoto T, Sakai H, Nishiyama K, Yamaji M, Fujii M, et al. Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure. Am Heart J. 2011;162:639–45.

    Article  CAS  PubMed  Google Scholar 

  36. Apple F, Steffen L, Pearce L, Murakami M, Luepker R. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin Chem. 2012;58(5):930–5.

    Article  CAS  PubMed  Google Scholar 

  37. McKie P, AbouEzzeddine O, Scott C, Mehta R, Rodeheffer R, Redfield M, et al. High-sensitivity troponin I and amino-terminal pro-B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem. 2014;60(9):1225–33. doi:10.1373/clinchem.2014.222778.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel R, Tuovinen T, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2013;35(5):271–81.

    Article  PubMed  Google Scholar 

  39. Neeland I, Drazner M, Berry J, Ayers C, deFilippi C, Seliger S, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol. 2013;61(2):187–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Seliger S, de Lemos J, Neeland I, Christenson R, Gottdiener J, Drazner M, et al. Older adults, “malignant” left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure. JACC Heart Fail. 2015;3(6):445–55.

    Article  PubMed  Google Scholar 

  41. Pokharel Y, Sun W, de Lemos J, Taffet G, Virani S, Ndumele C, et al. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2014;65(1):78–84. Important paper that showed how troponin levels are useful in assessing those with risk factors such as HTN.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy J, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–9.

    Article  PubMed  Google Scholar 

  44. Messer J. C-reactive protein and cardiovascular disease. Circulation. 2006;114(7):e253–4.

    Article  Google Scholar 

  45. Miller V, Redfield M, McConnell J. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol. 2007;5(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  46. Lyngbaek S, Winkel P, Gotze J, Kastrup J, Gluud C, Kolmos H, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol. 2013;21(10):1275–84.

    Article  PubMed  Google Scholar 

  47. Agarwal S, Chambless L, Ballantyne C, Astor B, Bertoni A, Chang P, et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail. 2012;5(4):422–9.

    Article  PubMed Central  PubMed  Google Scholar 

  48. D’Agostino R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.

    Article  PubMed  Google Scholar 

  49. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008;1(2):125–33. doi:10.1161/circheartfailure.108.768457.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499–510.

    Article  PubMed  Google Scholar 

  51. Nambi V, Liu X, Chambless L, de Lemos J, Virani S, Agarwal S, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk: the atherosclerosis risk in communities study. Clin Chem. 2013;59(12):1802–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J. 2009;30:162–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic induced reversible myocardial ischemia. Clin Chem. 2008;54:1234–8.

    Article  CAS  PubMed  Google Scholar 

  54. Keller T, Munzel T, Blankenberg S. Making it more sensitive: the new era of troponin use. Circulation. 2011;123(13):1361–3.

    Article  PubMed  Google Scholar 

  55. Sawaya H, Sebag I, Plana J, Januzzi J, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Sawaya H, Sebag I, Plana J, Januzzi J, Ky B, Tan T, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Brush J, Cannon R, Schenke W, Bonow R, Leon M, Maron B, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319(20):1302–7.

    Article  PubMed  Google Scholar 

  58. Picchi A. Coronary microvascular dysfunction in diabetes mellitus: a review. World J Cardiol. 2010;2(11):377.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Tsujita K, Yamanaga K, Komura N, Sakamoto K, Miyazaki T, Ishii M, et al. Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol. 2015;187:411–3.

    Article  PubMed  Google Scholar 

  60. Folsom A, Yao L, Alonso A, Lutsey P, Missov E, Lederle F, et al. Circulating biomarkers and abdominal aortic aneurysm incidence. Circulation. 2015;132(7):578–85.

    Article  CAS  PubMed  Google Scholar 

  61. Schneider A, Rawlings A, Sharrett A, Alonso A, Mosley T, Hoogeveen R, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J. 2014;35(27):1817–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Bansal N, Hyre Anderson A, Yang W, Christenson R, de Filippi C, Deo R, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol. 2014;26(4):946–56.

    Article  PubMed  Google Scholar 

  63. Pohlhammer J, Kronenberg F, Rantner B, Stadler M, Peric S, Hammerer-Lercher A, et al. High-sensitivity cardiac troponin T in patients with intermittent claudication and its relation with cardiovascular events and all-cause mortality—The CAVASIC Study. Atherosclerosis. 2014;237(2):711–7.

    Article  CAS  PubMed  Google Scholar 

  64. deFilippi C, de Lemos J, Tkaczuk A, Christenson R, Carnethon M, Siscovick D, et al. Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk in older adults. J Am Coll Cardiol. 2012;60(24):2539–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Ahmad T, Fiuzat M, Mark D, Neely B, Neely M, Kraus W, et al. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. Am Heart J. 2014;167(2):193–202.e1.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

    Article  CAS  PubMed  Google Scholar 

  67. Everett B, Zeller T, Glynn R, Ridker P, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):1851–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Jhund P, Claggett B, Voors A, Zile M, Packer M, Pieske B, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014;7(6):953–9.

    Article  CAS  PubMed  Google Scholar 

  69. McMurray J, Packer M, Desai A, Gong J, Lefkowitz M, Rizkala A, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. Study that recently showed that therapy with neprilysin demonstrated a decrease in adverse clinical events with established HF. Study also incidentally found that the decrease in adverse clinical events was associated with troponin decrease as well.

    Article  PubMed  Google Scholar 

  70. Metra M, Cotter G, Davison B, Felker G, Filippatos G, Greenberg B, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program. J Am Coll Cardiol. 2013;61(2):196–206.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Vijay Nambi declares support from a VA MERIT grant, 1I01CX001112-01; to being a co-investigator on a provisional patent filed by Roche “Biomarkers to Improve Prediction of Heart Failure Risk” (Patent No. 61721475); receiving personal fees for being a national monitor for a study sponsored by Anthera; and to having served in the regional advisory board for Sanofi-Regeneron. Dr. Nambi is employed at the Michael E. Debakey VA Medical Center.

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Houston, TX, USA

    Jason Hoff & Vijay Nambi

  2. Michael E DeBakey Veterans Affairs Hospital, Houston, TX, USA

    William Wehner & Vijay Nambi

  3. Center for Cardiovascular Prevention Methodist DeBakey Heart and Vascular Center, Houston, TX, USA

    Vijay Nambi

Authors
  1. Jason Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Wehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vijay Nambi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vijay Nambi.

Ethics declarations

Conflict of Interest

Jason Hoff declares no conflicts of interest.

William Wehner declares being employed at the Michael E. Debakey VA Medical Center. He declares no other conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclaimer

The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoff, J., Wehner, W. & Nambi, V. Troponin in Cardiovascular Disease Prevention: Updates and Future Direction. Curr Atheroscler Rep 18, 12 (2016). https://doi.org/10.1007/s11883-016-0566-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-016-0566-5

Keywords

Search

Navigation